Related Experiment Videos
Vancomycin pharmacokinetics and dosing in premature neonates
A McDougal1, E W Ling, M Levine
1Department of Pharmacy, British Columbia's Children's Hospital, University of British Columbia, Vancouver, Canada.
Therapeutic Drug Monitoring
|August 1, 1995
Summary
This study evaluated vancomycin dosing in premature neonates, finding the protocol achieved target peak levels in most infants but undershot trough levels. Clearance increased with postconceptional age, suggesting individualized dosing may be beneficial.
Area of Science:
- Neonatal Pharmacology
- Pediatric Infectious Diseases
Background:
- Vancomycin is crucial for treating Gram-positive infections in neonates.
- Optimizing vancomycin dosing in premature infants is challenging due to immature organ function and variable pharmacokinetics.
Purpose of the Study:
- To assess the pharmacokinetic parameters of vancomycin in premature neonates using a standardized dosing protocol.
- To evaluate the effectiveness of the protocol in achieving therapeutic vancomycin concentrations.
- To identify factors influencing vancomycin clearance and half-life in this population.
Main Methods:
- Prospective study of 44 premature neonates stratified into four postconceptional age (PCA) groups.
- Vancomycin administered based on a specific dosage protocol for each PCA group.
- Pharmacokinetic parameters calculated from peak and trough serum vancomycin concentrations at steady state.
Main Results:
- The protocol achieved target peak vancomycin concentrations in 64% of neonates in PCA Groups I-III.
- Target trough concentrations were frequently undershot.
- Volume of distribution (Vd) was constant (0.56 L/kg), while clearance increased significantly with PCA.
- Elimination rate constant and half-life correlated with PCA.
Conclusions:
- The established vancomycin dosing protocol is partially effective in achieving therapeutic peak concentrations in premature neonates.
- Infant postconceptional age is a key determinant of vancomycin clearance and half-life.
- Individualized vancomycin dosing, considering Vd and PCA-based clearance, may improve therapeutic outcomes.